GlassScriptPhysician profile
Caroline C Kinney
NPI 1871006056
$3,813.59
in general payments reported to CMS, 2019-2025
34 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,020 · 2022: $773 · 2023: $1,232 · 2024: $664 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $457.87 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $389.61 | 2021-2024 | Lynparza, Enhertu, Epanova |
| Celgene Corporation | $369.42 | 2021-2023 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $311.96 | 2021-2023 | Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $308.97 | 2022-2025 | |
| Janssen Biotech, INC. | $293.39 | 2021-2024 | Tecvayli, Darzalex, Talvey |
| E.R. Squibb & Sons, L.L.C. | $207.45 | 2022-2023 | Pomalyst, Opdualag |
| Progenics Pharmaceuticals, INC. | $147.13 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $128.19 | 2023 | Tavalisse, Rezlidhia |
| Abbvie INC. | $125.47 | 2023-2025 | |
| Astellas Pharma US INC | $114.48 | 2021-2024 | Xtandi |
| Glaxosmithkline, LLC. | $114.09 | 2022-2023 | Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $111.67 | 2022-2024 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $104.84 | 2022-2023 | Lumakras, Kyprolis, Vectibix |
| Apellis Pharmaceuticals, INC. | $83.56 | 2023 | Empaveli |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $70.83 | 2024 | Epkinly |
| Mirati Therapeutics, INC. | $45.96 | 2023 | Krazati |
| Taiho Oncology, INC. | $41.96 | 2024 | |
| Exelixis INC. | $39.99 | 2023 | Cabometyx |
| Array Biopharma INC | $36.21 | 2023 | Lorbrena, Mektovi, Braftovi |
| Incyte Corporation | $33.29 | 2023-2024 | Monjuvi, Jakafi |
| Pfizer INC. | $27.89 | 2024 | |
| Daiichi Sankyo INC. | $27.67 | 2024 | Enhertu |
| Sumitomo Pharma America, INC. | $24.48 | 2023 | Orgovyx |
| Jazz Pharmaceuticals INC. | $24.35 | 2023 | |
| Alnylam Pharmaceuticals INC. | $24.20 | 2022 | |
| Genzyme Corporation | $23.87 | 2021 | |
| Genentech USA, INC. | $22.08 | 2023 | Gavreto, Alecensa, Phesgo |
| Servier Pharmaceuticals LLC | $19.18 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $18.07 | 2023 | Libtayo |
| Karyopharm Therapeutics INC. | $17.10 | 2023 | Xpovio |
| Gilead Sciences, INC. | $16.55 | 2023 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $16.29 | 2021 | |
| Pharmaessentia USA Corporation | $15.52 | 2023 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Kinney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.